
Colorectal Cancer
Latest News
Latest Videos

Podcasts
More News

Press Release
Forget the outdated image of colon cancer as a disease for the elderly. The new, and increasingly common, faces of this disease are pictured here.

Press
Majority of Americans say they don’t have time for colorectal cancer screening, prioritizing household chores instead of their health.

Knowledge gaps and dismissed symptoms may contribute to rising deaths in younger adults.

The U.S. FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer.

Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial.

There are a number of pulmonary embolism warning signs patients with cancer and their caregivers should watch for.

I never thought about mantras until my diagnosis with colon cancer at the age of 34.

Dietitians share a fiber- and protein-rich pastina bean soup to help patients with colorectal cancer stay nourished and manage gastrointestinal symptoms during treatment.

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers.

The FDA accepted a new drug application for zanzalintinib plus immunotherapy after showing improved survival in some previously treated colorectal cancers.

A phase 2 trial showed onvansertib plus FOLFIRI and Avastin improved response and disease control in first-line RAS-mutated metastatic colorectal cancer.

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

Press Release
Colorectal Cancer Alliance urges action through Project Cure CRC.

Dr. Nicholas Hornstein explained the concept of ctDNA and how this blood test may help guide treatment decisions, including whether additional therapy is needed.

In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients with BRAF V600E mCRC.

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

Physical activity, especially walking, was linked to less fatigue and better quality of life for patients with colorectal cancer, particularly in early survivorship.

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

Patients with stage 3 colorectal cancer who tested MRD-positive with Signatera after surgery saw a meaningful survival benefit from Celebrex plus chemotherapy.

The FDA granted fast track status to muzastotug plus Keytruda for adults with microsatellite stable metastatic colorectal cancer without liver metastases.

Dr. Joshua Sabari sat down with Dr. Michael Cecchini to discuss advances in colorectal cancer management and key data presented at the 2025 ESMO Congress.

Press Release
$100 Million Initiative by Colorectal Cancer Alliance Aims to Accelerate Progress.

After a surprise diagnosis at 47, salon owner Christa Messmer found strength, faith and renewed meaning in life while facing colorectal cancer.

The FDA grants fast track status to alnodesertib plus low-dose irinotecan for third-line metastatic colorectal cancer with ATM deficiency.

Colorectal cancer is a complex disease. Understanding its fundamental aspects can empower you to have more informed and productive conversations with your oncologist.














